Early Charm Ventures, a venture studio that converts science to business, today announced the hiring of Olumide Kayode, PhD – a Mayo Clinic and National Cancer Institute (NCI)-trained scientist – in a move to bolster its Drug Discovery and Aquaculture company portfolios.

Dr. Kayode joins the Early Charm team as an ardent structural biologist with detailed knowledge of protease biology and enzyme catalysis. His research experience includes stints with the Cancer Research Training Program within the NCI as well as with the Mayo Clinic Graduate School focusing on Molecular Pharmacology and Experimental Therapeutics. Dr. Kayode will initially focus on Revolve Technologies, one of Early Charm’s Drug Discovery portfolio companies.

"Much of our Early Charm company portfolio relies on understanding proteins, including Revolve, SilcsBio, Rasio Therapeutics, Abri Science, VakSea and Gaskiya Diagnostics,” says Alex Meltzer, PhD, CEO of Revolve and Principal with Early Charm. “Dr. Kayode’s knowledge brings to a new level our growing scientific team of protein experts. His expertise will help anchor our drug discovery (life science) technical team and drive our companies forward.”

About Early Charm Ventures:

Early Charm Ventures is a venture studio, founded in 2012 in Baltimore, that converts science to business. Early Charm specializes in taking brilliant scientific discoveries made at universities and turning them into companies focused on growth. Our best successes come from teaming with entrepreneurial-minded faculty who are rooted in tools for drug design, custom materials, aquaculture technologies and machine vision. Ultimately, we bring to the table our deep experience co-founding companies with leading researchers. With these exceptional people and their ideas, we partner with them to advance or even create whole new industries. Learn more: www.earlycharm.com